Skip to main content
Michael Overman, MD, Oncology, Houston, TX

MichaelJOvermanMD

Oncology Houston, TX

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor at MD Anderson Cancer Center

Dr. Overman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Overman's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Los Angeles County-Harbor-UCLA Medical Center
    Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - Present
  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • GA State Medical License
    GA State Medical License 2023 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2004 - 2026
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients with Cancer  
    Michael J Overman, Adi Diab, Patrick Hwu, JAMA Network Open
  • Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge  
    B Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology

Lectures

  • How to Approach Biomarker Testing for Colorectal Cancer in 2019 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
  • A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without ... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (pa... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Join now to see all

Other

Authored Content

  • Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients with CancerJuly 2020

Press Mentions

  • MD Anderson Research Highlights Special Edition: ESMO 2024
    MD Anderson Research Highlights Special Edition: ESMO 2024September 10th, 2024
  • Six-Time Cancer Survivor: How My Diagnoses Led Me to MD Anderson
    Six-Time Cancer Survivor: How My Diagnoses Led Me to MD AndersonApril 7th, 2023
  • First Patient Dosed in Nouscom Colorectal Cancer Study
    First Patient Dosed in Nouscom Colorectal Cancer StudyNovember 15th, 2022
  • Join now to see all

Professional Memberships